Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Rationale for targeting the Ras/MAPK pathway in triple-negative breast cancer.

Discovery medicine - 1 May 2014

Giltnane Jennifer M, Balko Justin M

Abstract excerpt

"Triple negative" breast cancer (TNBC) is the most aggressive and least common clinical subtype of breast cancer. As its nomenclature implies, TNBC lacks specific biomarker expression marking response to an effective targeted therapy. The incidence of TNBC is higher in young minority women who suffer from high rates of early recurrence and death from their disease. Mounting preclinical evidence supports targeting...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Enzyme Inhibitors
Share to Gene Expression Regulation, Neoplastic
Share to Genome, Human

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to MAP Kinase Kinase Kinases

Share to MAP Kinase Signaling System

Share to Neoplasm Recurrence, Local

Share to ras Proteins

Share to Triple Negative Breast Neoplasms

Source

Identifiers

PMID: 24882719

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Rationale for targeting the Ras/MAPK pathway in triple-negative breast cancer.PMID 24882719Read ↗

Advances in the Understanding of the Pathogenesis of Triple-Negative Breast Cancer.Semantic proximity Read ↗

Divide and Conquer—Targeted Therapy for Triple-Negative Breast CancerSemantic proximity Read ↗

Molecular pathways and therapeutic targets linked to triple-negative breast cancer (TNBC).Semantic proximity Read ↗

Triple-negative breast cancer and the need for new therapeutic targets.Semantic proximity Read ↗

Molecular targets and therapies associated with poor prognosis of triple‑negative breast cancer (Review)Semantic proximity Read ↗

Therapeutic landscape in mutational triple negative breast cancerSemantic proximity Read ↗

Triple-negative breast cancer: Molecular features, pathogenesis, treatment and current lines of researchSemantic proximity Read ↗

Triple-negative breast cancer.Semantic proximity Read ↗

Molecular Biology Mechanisms and Emerging Therapeutics of Triple-Negative Breast CancerSemantic proximity Read ↗

Molecular Pathways: PI3K Pathway Targets in Triple-Negative Breast CancersSemantic proximity Read ↗

Molecular Basis of Triple Negative Breast Cancer and Implications for TherapySemantic proximity Read ↗

Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.